GlassScriptPhysician profile
Sean Patrick Hurley
NPI 1700936598
$4,635.99
in general payments reported to CMS, 2019-2025
32 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $557 · 2021: $511 · 2022: $855 · 2023: $517 · 2024: $632 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $66.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.59 |
| Education | $66.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $679.22 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.85 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $297.79 | 2022-2025 | |
| Janssen Biotech, INC. | $244.75 | 2021-2025 | Tremfya, Stelara |
| Celgene Corporation | $227.97 | 2021-2023 | Zeposia |
| Pfizer INC. | $193.57 | 2019-2025 | |
| Medtronic, INC. | $175.61 | 2022-2025 | Pillcam |
| Ferring Pharmaceuticals INC. | $149.57 | 2019-2025 | Rebyota |
| Gilead Sciences, INC. | $135.70 | 2019-2024 | |
| Ardelyx, INC. | $69.98 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $59.64 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $56.42 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $55.80 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $54.61 | 2023-2024 | Dupixent |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $36.05 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $32.01 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $27.25 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $25.72 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $23.31 | 2025 | Iqirvo |
| Novo Nordisk INC | $20.84 | 2025 | Wegovy |
| Romark Laboratories, Lc | $20.56 | 2020 | |
| Ethicon US, LLC | $19.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.53 | 2022 | |
| Aimmune Therapeutics, INC. | $18.44 | 2025 | Zenpep |
| Capsovision, INC. | $17.49 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $16.23 | 2020 | |
| Vivus LLC | $16.12 | 2025 | Qsymia |
| Alfasigma USA, INC. | $14.78 | 2020 | |
| Olympus America INC. | $14.78 | 2024 | Endoclot Phs |
| Ironwood Pharmaceuticals, INC | $13.33 | 2020 | |
| Shionogi INC | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.